Recent advances in cytokine synthesis inhibitors

IDrugs

Volumn 3, Issue 7, 2000, Pages 774-782

  Iwamura, Hiroyuki ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748364118     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Amano Y, Lee SW, Allison AC: Inhibition by glucocorticoids of the formation of interleukin-1α, interleukin-1β, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol (1993) 43:176-182.
2. Yoshimura N, Matsui S, Hamashima T, Oka T: Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation (1989) 47:351-356.
3. Hiroi J, Sengoku T, Morita K, Kishi S, Sato S, Ogawa T, Tsudzuki M, Matsuda H, Wada A, Esaki K. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol (1998) 76:175-183.
4. Moreland LW: Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol (1999) 57(Suppl):7-15.
5. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN: Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc (1998) 30:4126-4127.
6. Marshall PJ, Griswold DE, Breton J, Webb EF, Hillegass LM, Sarau HM, Newton Jr J, Lee JC, Bender PE, Hanna N: Pharmacology of the pyrroloimidazole, SK&F 105809-I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol (1991) 42:813-824.
7. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemence IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739-746.
8. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 279:1453-1461.
9. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 15:1914-1923.
10. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther (1998) 284:687-692.
11. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 43:175-183.
12. Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ: 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b] pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J Med Chem (1998) 41:4196-4198.
13. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ: RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 291:680-687.
14. Yamamoto N, Sakai F, Yamazaki H, Kawai Y, Nakahara K, Okuhara M: Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol (1996) 23:1778-1783.
15. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M: Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol (1996) 314:137-142.
16. Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, Okuhara M: FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock. Eur J Pharmacol (1997) 327:169-174.
17. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharm (1993) 15:409-413.
18. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith III EF, Lee JC, Esser KM: Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharm (1994) 16:805-816.
19. Foissier L, Lonchampt M, Coge F, Canet E: In vitro downregulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther (1996) 278:1484-1490.
20. Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G, Alexander R, Head J, Boyd E, Eaton M, Perry M, Wales M, Smith B, Owens R, Catterall C, Lumb S, Russell A, Allen R, Merriman M, Bloxham D, Higgs G: The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br J Pharmacol (1996) 118:1183-1191.
21. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ: Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther (1995) 273:1396-1402.
22. Saccomano NA, Vinick FJ, Koe BK, Nielsen JA, Whalen WM, Meltz M, Phillips D, Thadieo PF, Jung S, Chapin DS, Lebel LA, Russo LL, Helweg DA, Johnson JL, Ives JL, Williams IH: Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxy phenyl]-2-imidazolidinones. J Med Chem (1991) 34:291-298.
23. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol (1996) 118:649-658.
24. Souness JE, Houghton C, Sardar N, Withnall MT: Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors. Biochem Pharmacol (1999) 58:991-999.
25. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE: Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol (1994) 113:1423-1431.
26. Iwasaki T, Kondo K, Kuroda T, Moritani Y, Yamagata S, Sugiura M, Kikkawa H, Kaminuma O, Ikezawa K: Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. J Med Chem (1996) 39:2696-2704.
27. Kaminuma O, Kikkawa H, Matsubra S, Ikezawa K: Inhibitory effect of a novel phosphodiesterase IV inhibitor, T-440, on antigen- and chemical mediator-induced broncho-constrictions in guinea pigs in vivo. Jpn J Pharmacol (1996) 72:1-8.
28. Kaminuma O, Mori A, Suko M, Kikkawa H, Ikezawa K, Okudaira H: Interleukin-5 production by peripheral blood mononuclear cells of asthmatic patients is suppressed by T-440: relation to phosphodiesterase inhibition. J Pharmacol Exp Ther (1996) 279:240-246.
29. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ: SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther (1998) 284:420-426.
30. Boichot E, Wallace JL, Germain N, Corbel M, Lugnier C, Lagente V, Bourguignon JJ: Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. J Pharmacol Exp Ther (2000) 292:647-653.
31. 2) receptor selective agonists. Int J Immunopharm (1995) 17:221-224.
32. 3 adenosine receptors. J Immunol (1996) 156:3435-3442.
33. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem (2000) 275:4429-34.
34. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B, Mullane KM: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol (1994) 152:5853-5859.
35. Cronstein BN, Naime D, Firestein G: The anti-inflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum (1995) 38:1040-1045.
36. Thomberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala LM, Casano FJ, Chin J, Ding GJF, Egger LA, Gaffeny EP, Limjuco G, Palyha OS, Raju SM, Roland AM, Salley JP, Yamin TT, Lee TD, Shively JE, MacCross M, Mumford RA, Schmidt JA, Tocci MJ: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature (1992) 356:768-774.
37. Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y, Takeuchi M, Shibanuma T, Isomura Y: Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex. Chem Pharm Bull (1999) 47:11-21.
38. McGeehan GM, Becherer JD, Bast Jr RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 370:558-561.
39. Dekkers PE, Lauw FN, ten Hove T, te Velde AA, Lumley P, Becherer D, van Deventer SJ, van der Poll T: The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-α (TNF-α) and TNF-α receptors during human endotoxemia. Blood (1999) 94:2252-2258.
40. Barlaam B, Bird TG, Lambert-Van Der Brempt C, Campbell D, Foster SJ, Maciewicz R. New α-substituted succinate-based hydroxamic acids as TNF-α convertase inhibitors. J Med Chem (1999) 42:4890-4908.
41. Kakutani M, Takeuchi K, Waga I, Iwamura H, Wakitani K: JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res (1999) 48:461-468.
42. Fong Y, Lowry SF: Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol (1990) 55:157-170.
43. Dinarelio CA, Wollf SM: The role of interleukin-1 in disease. New Engl J Med (1993) 328:106-113.
44. Echtenacher B, Mannel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature (1996) 381:75-77.
45. Sampaio EP, Sarno EN, Galilly R, Conn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 173:699-703.
46. Connolly JE, Rigby WFC: Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. Arthritis Rheum (1999) 42(Suppl):S91 121.
47. Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling DI: Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett (1998) 8:2669-2674.
48. Oliver SJ, Freeman SL, Corral LG, Ocampo CJ, Kaplan G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol (1999) 118:315-321.
49. Wauwe JV, Aerts F, Goossens J, Hieidi VG, Nyen GV: Identification of R146225 as a novel orally active inhibitor of interleukin-5 protein and mRNA production. 4th World Congress on Inflammation, Paris, France (1999).
50. SMITHKLINE BEECHAM CORP (Adams JL, Gallagher TF, Lee JC, White JR): Imidazole derivatives and their use as cytokine inhibitors. WO-09314081 (1993).
51. SMITHKLINE BEECHAM CORP (Adams JL, Gallagher TF, Garigipati RS, Boehm JC, Sisko J, Peng Z, Lee JC): Certain 1,4,5-Trisubstituted imidazoles useful as cytokine suppressors. WO-09621452 (1996).
52. SMITHKLINE BEECHAM CORP (Adams JL, Lee D): Novel substituted triazole compounds. WO-00010563 (2000).
53. ORTHO-MCNEIL INC (Dodd JH, Henry JR, Rupert K): Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. WO-09847899 (1998).
54. ORTHO-MCNEIL INC (Beers SA, Malloy E, Wachter MR Wu W): Substituted imidazoles useful in the treatment of inflammatory diseases. WO-09847892 (1998).
55. F HOFFMANN-LA ROCHE LTD (Labadie SS, Rotstein DM, Sjrogen EB, Talamas FS): Pyrazole derivatives as p-38 MAP kinase inhibitors. WO-09957101 (1999).
56. FUJISAWA PHARMACEUTICAL CO LTD (Oku T, Kawai Y, Murasawa Y, Yamazaki H, Abe Y): Pyrazole derivatives. US-05624931 (1997).
57. FUJISAWA PHARMACEUTICAL CO LTD (Oku T, Kawai Y, Marusawa H, Tanaka H): Imidazotriazine derivatives. WO-09212154 (1992).
58. FUJISAWA PHARMACEUTICAL CO LTD (Kawai Y, Yamazaki H, Tanaka H, Oku T): Pyrazole derivatives. US-05670503 (1997).
59. RHONE-POULENC RORER LTD (Ashton MJ, Cook DC, Fenton G, Hills SJ, Mcfarlane IM, Palfreyman MN, Ratcliff AJ, Vicker N): Benzamides. EP-00497564 (1992).
60. CELLTECH GROUP PLC (Warrellow GJ, Boyd EC, Alexander RP): Tri-substituted phenyl derivatives as phosphodiesterase inhibitors. WO-09414742 (1994).
61. TANABE SEIYAKU CO LTD (Iwasaki T, Kondo K, Ikezawa K, Kikkawa H, Yamagata S): Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor. US-05342941 (1994).
62. SMITHKLINE BEECHAM CORP (Christensen SB): Compounds useful for treating allergic and inflammatory diseases. WO-09319749 (1993).
63. WARNER-LAMBERT CO (Conner DT, Menetski JP): Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use. WO-09926616 (1999).
64. TAIHO PHARMACEUTICAL CO LTD (Yamada S, Hosoya T, Kitagawa K, Inoue S, Kiniwa M, Asao T): Benzimidazole derivatives and pharmaceutically acceptable salts thereof. WO-09924425 (1999).
65. MERCK & CO INC (Chapman KT, Thornberry NA, Bull HG, Weidner JR, Maccoss M, Mjalli AM): Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme. US-05434248 (1995).
66. YAMANOUCHI PHARMACEUTICAL CO LTD (Anami H, Okamoto Y, Moridaira K, Yonetoku Y, Terai Y, Takeuchi M): New sulfonamide derivative and medicine. JP-11147873 (1999).
67. MERCK & CO INC (Hagmann WK, Zhao JJ, MacCoss M, Mjalli AM): Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme. US-05866545 (1999).
68. VERTEX PHARMACEUTICALS INC (Wannamaker MW, Charifson P, Lauffer DJ, Mullican MD): 1,2-Diazepane derivatives as interleukin-1beta converting enzyme inhibitors. WO-09946248 (1999).
69. AMERICAN CYANAMID CO (Levin JI, Zask A, Gu Y): Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors. US-05977408 (1999).
70. JAPAN TOBACCO INC (Haruta J, Sakuma K, Watanabe Y): Amide compounds and use of the same. WO-09708133 (1997).
71. CELGENE CORP (Muller GW): Imides. US-05605914 (1997).
72. JANSSEN PHARMACEUTICA NV (Lacrampe JFA, Freyne EJE, Venet MG, Boeckx GM): IL-5 inhibiting 6-azauracil derivatives. WO-09902505 (1999).
73. YOSHITOMI PHARMACEUTICAL IND LTD (Sueoka H, Yamamoto K, Sugahara K, Yasuoka J, Nishiyama A, Kiuchi M): Novel imidazole derivatives as cytokine synthesis inhibitors. WO-09933827 (1999).
74. TAISHO PHARMACEUTICAL CO LTD (Saito S, Matsumoto T, Nakamura T): N-substituted nitroaniline derivatives. JP-12007626 (2000).